Quest Diagnostics (DGX) finalizes its previously-announced acquisition of Solstas Lab Partners Group.
On the basis of the purchase, the company ups its 2014 guidance to revenue growth of 2% - 4% versus the previous forecast of flat to down 2%.
EPS forecast now $3.95 - $4.15 up from $3.90 - $4.10.
Q1 EPS will be negatively impacted $0.10 due to harsh winter weather. Current consensus estimate is $0.93/share on revenues of $1.8B.